Introduction {#Sec1}
============

To date, various nanomedicines have been developed and commercially applied in clinical and non-clinical areas. Nanomedicines have shown essential characteristics such as efficient transport through fine capillary blood vessels and lymphatic endothelium, longer circulation duration and blood concentration, higher binding capacity to biomolecules (e.g. endogenous compounds including proteins), higher accumulation in target tissues, and reduced inflammatory or immune responses and oxidative stress in tissues. These characteristics differ from those of conventional medicines depending on physiochemical properties (e.g.; particle surface, size and chemical composition) of the nano-formulations (De Jong and Borm [@CR11]; Liu et al. [@CR57]; Onoue et al. [@CR75]). Efforts to develop these characteristics of nanomedicines are likely to make them available for treatment of specific diseases which have not been efficiently controlled using conventional medicines, because nanomedicines allow more specific drug targeting and delivery, greater safety and biocompatibility, faster development of new medicines with wide therapeutic ranges, and/or improvement of in vivo pharmacokinetic properties (Onoue et al. [@CR75]). Many nanomedicines have been used for the purpose of increasing efficacy and reducing adverse reactions (e.g., toxicity) by altering efficacy, safety, physicochemical properties, and pharmacokinetic/pharmacodynamic properties of the original drugs (Dawidczyk et al. [@CR10]). In particular, higher oral bioavailability or longer terminal half-life can be expected in case of orally administered nanomedicines, leading to reduction of administration frequency, dose and toxicity (Charlene et al. [@CR8]; Dawidczyk et al. [@CR10]). Regulation of pharmacokinetic characteristics of nanomedicines can results in significant advances in their utilization. Considerations of pharmacokinetic characteristics of nanomedicines and formulability for development purposes, direction and status of their development, and evaluation systems are thought to have important implications for effective development and use of more effective and safe nanomedicines. Therefore, we will present examples of effective go/stop evaluation stages through a review of pharmacokinetic characteristics and delivery of nanomedicines, and the status and processes of nanomedicine evaluation by global regulatory agencies through comparative analysis.

Delivery and pharmacokinetics of nanomedicines {#Sec2}
----------------------------------------------

Changes in pharmacokinetic characteristics of nanomedicines are due to changes in pharmacokinetic properties of their active pharmaceutical ingredients (API), which include longer stay in the body and greater distribution to target tissues, possibly increasing their efficacy and alleviating adverse reactions (Onoue et al. [@CR75]). Regulation of efficacy and/or adverse reactions of nanomedicines is affected by alteration of pharmacokinetics such as in vivo absorption, distribution, metabolism and excretion in the body.

Physiochemical properties of nanomedicines depend on their composition and formulation, which ultimately affect their efficacy and toxicity (EMA [@CR22]; TGA [@CR92]). Control of physiochemical properties (e.g. composition or formulation) of nanomedicines and adjustment of the degree of binding between nanomedicines and biomolecules eventually regulate in vivo distribution of nanomedicines (EMA [@CR22], [@CR23]; TGA [@CR92]). For example, it has been reported that the type and amount of binding proteins are significantly reduced when nanomedicines are prepared using PEGylated particles. Further, binding of polysorbate coated particles to ApoE was reported to increase their migration to the brain (EMA [@CR22]; TGA [@CR92]).

Based on the above concepts connecting and efficacy/toxicity, Table [1](#Tab1){ref-type="table"} shows targeted delivery methods that can lead to changes in the pharmacokinetics of nanomedicines in the body. Delivery mechanisms of nanomedicines can be divided into intracellular transport, epileptic transport and other types (Table [1](#Tab1){ref-type="table"}). Intercellular transport is regulated and facilitated by intracellularization, transporter-mediated endocytosis, and permeation enhancement through interactions involving particle size and/or cell surface (Francis et al. [@CR33]; Jain and Jain [@CR42]; Petros and DeSimone [@CR79]; Roger et al. [@CR84]). In general, a smaller particle size of nanomedicines increases intercellular transport, which facilitates cell permeation and affects absorption, distribution, and excretion of nanomedicines. In particular, cell internalization by transporter-mediated endocytosis depends on particle size of nanomedicines. When nanomedicine particles are large, opsonization occurs rapidly and their removal from the blood by endothelial macrophages is accelerated. It has been reported that affinity of cell surface transporters to nanomedicines varies depending on the particle size of nanomedicines, and this could also influence rapid removal of large particles from the blood by macrophages. In addition, nanomedicines containing non-charged polymers, surfactants, or polymer coatings which degrade in in vivo due to their hydrophilicity, interact with cell surface receptors or ligands to increase permeability or promote internalization of nanomedicines (Francis et al. [@CR33]; Jain and Jain [@CR42]; Petros and DeSimone [@CR79]; Roger et al. [@CR84]).

Table 1Target delivery characteristics related to pharmacokinetic properties of nanomedicinesTargeting methodsMechanismResultsIntercellular transport Cell internalizationCaveolar-mediated endocytosis (\< 60 nm)\
Clathrin-mediated endocytosis (\< 120 nm)Difference in intracellular defense mechanism depending on particle size\
Difference in affinity with cell surface transporter\
the easier the permeation to affect absorption, distribution and excretion by the smaller the particle size\
Removal from the blood by macrophages by large particles\
Increased permeability by changing the interaction with cell surface receptors or ligands by coating with polymers, surfactants Transporter-mediated endocytosisInteractions between molecules and nanoparticles by cell surface receptors in in vivo system Permeation acceleratorPerturbation of intracellular lipids by fatty acidsIntracellular transport Bioadhesive polymerOpening reversible tight junction and increase of membrane permeabilityImprovement of cytotoxic transport of intrinsic drugs by binding to specific proteins, antibodies and other in vivo polymers\
Anti-cancer drugs: Minimizing cytotoxicity in normal cells by reducing the anticancer effect of the site where the drug does not reach the tight junction and transferring it to the normal cells\
Reducing the elimination in lungs during inhalation ChelatorOpening reversible tight junction and increase of membrane permeabilityOthers EPR effectAccumulation in tumor cellsIncreased anticancer efficacy through increased permeability to cancerous tissue and prolongation of retention time (ie, accumulation) Conjugation with antibody, protein, peptide, polysaccharideSelective delivery to target tissuesControl of delivery to the target using receptor/ligand or physiologic specific days on the surface of the target cell enhances drug efficacy/reduction of adverse reactions Coated with unhygienic hydrophilic materialImproved stability and transport to mucus, prevention of opsonizationReduction of macrophage-induced or mucosal instability such that drugs stay in the body for a long time to increase drug efficacy/reduce harmful reactions Control of particle size to avoid removal by mucilage ciliaRetention extension in lung tissueDegradation in lung mucosa or alleviation of macrophage action

In addition, nanomedicines improve intracellular transport of active pharmaceutical ingredients through binding involving bioadhesive polymers or chelates (Table [1](#Tab1){ref-type="table"}) (Bur et al. [@CR7]; Des Rieux et al. [@CR12]; Devalapally et al. [@CR14]; Francis et al. [@CR33]; Jain and Jain [@CR42]; Mori et al. [@CR65]; Roger et al. [@CR84]). Increased intracellular trafficking of active pharmaceutical ingredients coupled to specific proteins, antibodies, and others in polymers in vivo occurs due to opening of tight junctions and/or increased membrane permeability. In particular, introduction of such a feature in anti-cancer agents can improve the effect of chemotherapy, including targeting brain tumors which are inaccessible to drugs bound by tight junctions, increasing tumor cell targeting, and reducing normal cell targeting. Cytotoxicity against normal cells can be minimized and anti-cancer efficacy achieved using such a nanomedicine strategy. Reduction of nanomedicine elimination in lungs during inhalation leads to increased due to reduced degradation and removal by lung mucosa or macrophages, resulting in increased drug retention time and movement of drug to the target.

Using the enhanced permeability and retention (EPR) effect, it is possible to increase anti-cancer efficacy through increasing tumor permeation and retention time. The EPR effect also makes it possible to selectively deliver nanomedicines to target tissue via conjugation to an antibody, protein, peptide, or polysaccharide, which can be used to modify delivery of nanomedicines to target tissues using receptor/ligand interactions or other physiologically specific target cell interactions, modulating drug efficacy or adverse reactions. Nanomedicines coated with hydrophilic material have improved stability, and their opsonization or accumulation in mucus is prevented. By inhibiting macrophage-induced or mucosal instability, nanomedicines can be retained in vivo, e.g., in lung tissue for prolonged periods of time through particle size, control and avoiding removal by mucus ciliates, which could lead to degradation or macroscopic effects in lung mucosa (Bur et al. [@CR7]). Therefore, a variety of formulations have been developed to use delivery mechanisms which can control pharmacokinetics and pharmacodynamics of nanomedicines.

Classification and pharmacokinetic properties of nanomedicines {#Sec3}
--------------------------------------------------------------

Nanomedicines exhibit a range of in vivo kinetic characteristics depending on their formulations. In this context, disadvantages and advantages of each type of formulation commonly used in nanomedicines (Devalapally et al. [@CR14]) are summarized, and pharmacokinetic properties of various nanomedicines formulations are shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.

Table 2Classification of nanomedicines considering pharmacokinetic propertiesFormulationsPharmacokinetic propertiesOthersAdvantagesDisadvantagesDendrimersPolysine\
Poly(amidoamine)\
PEGylated polylysine\
Lactoferrin-conjugatedHigh permeability\
Release control\
Drug-selective delivery\
Improved solubilityLimit of administration routesLow immunogenicity\
Blood toxicityEngineered nanoparticlesNanocrystal\
SoluMatrix fine particle\
Nanosized amorphousImproved systemic exposure\
Increased retention time in mucus\
Various routes of administrationInsufficient persistent emissionGastric mucosal irritation relief of NSAIDs\
Toxicity by higher CmaxLipid nanosystemsEmulsion\
Liposome\
Solid lipid nanoparticle\
Lectin-modified solid lipidDegradation or metabolism of formulated materials\
Improved systemic exposure\
Drug-selective delivery\
Accumulation in tumor cellsQuick removal by RES uptake\
Limit of administration routesLow toxicity and antigenicity\
Cytotoxicity due to surfactantMicellesHigh permeability\
Improved solubility\
Improved systemic exposureInsufficient persistent emissionLow immunogenicity\
Cytotoxicity due to surfactantPolymeric nanoparticlesEthyl cellulose/casein\
PLGA alginate, PLGA\
PLA-PEG\
Hydrogel\
Albumin\
Chitosan analogStable drug release in in vivo\
Increased retention time of drugRequired initial burst protection\
Limit of administration routesLow immunogenicity\
Required removal of non-degradable polymer

Table 3Specific pharmacokinetic characteristics of drugs based on the classification of nanomedicinesFormulationsAPITechniquesAdministration routesPK propertiesDendrimerDoxorubicinPolylysine dendrimerIVIncrease of systemic exposure, accumulation in tumor cellsFlurbiprofenPoly(amidoamine) dendrimerIVIncrease of distribution and retentions in inflammatory sitesMethotrexatePEGylated polylysine dendrimerIVProlongation of systemic exposureLactoferrin-conjugated dendrimerIVAccumulation in lungsPiroxicamPoly(amidoamine) dendrimerIVProlongation of systemic exposureEngineered NPsCarbendazimNanocrystalsPOIncrease of oral FCilostazolNanocrystalsPOIncrease of oral FCurcuminNanocrystalsPOIncrease of oral FDanazolNanocrystalsPOIncrease of oral FDiclofenacSoluMatrix™ fine particlePORapid absorption, pain reliefFenofibrateNanocrystalsPOIncrease of oral FIndomethacinSoluMatrix fine particlePORapid absorptionMegestrol acetateNanocrystalsPOIncrease of oral FNitrendipineNanocrystalsPOIncrease of oral FNobiletinNanosized amorphous particlesPOIncrease of oral F, liver protective effectTranilastNanocrystalsPOIncrease of oral F, rapid absorptionInhalable nanocrystalline powdersLungsIncrease of anti-inflammatory effect in lungsPaclitaxelAlbumin nanoparticlesIVTumor targetingLipidEmulsionCinnarizineSelf-emulsifying drug deliveryPOIncrease of oral FCoenzyme Q10Solid self-emulsifying deliveryPOIncrease of oral FCyclosporin ASelf-emulsifying drug deliveryPOIncrease of oral FInhalable dry emulsionsLungsIncrease of anti-inflammatory effect in lungsHalofantrineSelf-emulsifying drug deliveryPOIncrease of oral FSimvastatinSelf-emulsifying drug deliveryPOIncrease of oral FLiposomesAmikacinLiposome (Phospholipid/Chol)IVIncrease of half-lifeAmphotericin BLiposome (PC/Chol/DSPG)IVIncrease of systemic exposure, decrease of RES uptakeCytarabine/daunorubicinLiposome (DSPC/DSPG/Chol)IVCL reductionDoxorubicinLiposome, PEGylated liposomeIVIncrease of distribution in tumor cellsO-palmitoyl tilisololLiposome (PC/Chol)IVIncrease of distributionPaclitaxelLiposome (PC/PG)IVProlongation of systemic exposurePrednisoloneLiposome (PC/Chol/10% DSPE-PEG2000)IVProlongation and increase of systemic exposureSolid lipid NPsAzidothymidineSolid lipid NPsIVIncrease of permeability and retention time in brainClozapineSolid lipid NPsIVIncrease of systemic exposure, CL reductionDiclofenac NaSolid-in-oil NPsSkinIncrease of percutaneous absorptionInsulinLectin-modified solid lipid NPsPOIncrease of oral FLidocaineSolid lipid nanoparticlesSkinRegulation of skin permeabilityMicellesCamptothecinBlock copolymeric micellesIVIncrease of systemic exposureDoxorubicinBlock copolymeric micellesIVIncrease of systemic exposure, CL reductionPaclitaxelBlock copolymeric micellesIVIncrease of systemic exposure, CL reductionPilocarpineBlock copolymeric micellesEyesIncrease of efficacyTranilastSelf-micellizing solid dispersionPOIncrease of oral FPolymeric NPsCelecoxibEthyl cellulose/casein NPsPOIncrease of oral FClotrimazole/econazolePLGA and alginate NPsPOIncrease of oral FDocetaxelPLA-PEG NPsIVIncrease of half-life and anti-cancer effectDoxorubicinPLGA NPsIV, IPIncrease of half-life, decrease of distribution in heartGlucagonPLGA NPsLungsIncrease of half-life, increase of oral FGlucagonPLGA NPsLungsIncrease of oral F and half-lifeInsulinHydrogel NPsPOIncrease of oral FRifampicinPLGA NPsPOIncrease of oral FsiRNAChitosan analog NPsPOIncrease of systemic exposure, gene silencingVIP derivativePLGA NPsLungsAnti-inflammatory effect

### Dendrimers {#Sec4}

Dendrimers are characterized by the presence of polysine, poly(amidoamine), PEGylated polylysine, or lactoferrin-conjugated formulations, with high membrane permeability, controlled release ability, selective delivery of active pharmaceutical ingredients, and solubility improvement. There have been reports of limitations in route of administration and immunogenicity, and blood toxicity cases have also been reported (Devalapally et al. [@CR14]; Kawabata et al. [@CR51]; Liu and Fréchet [@CR56]; Mora-Huertas et al. [@CR63]). Applications of dendrimer technology to active pharmaceutical ingredients are exemplified in several reports (Asthana et al. [@CR2]; Barenholz [@CR3]; Chaturvedi et al. [@CR9]; Fanciullino et al. [@CR24]; Feldman et al. [@CR29]; Fetterly and Straubinger [@CR30]; Hanafy et al. [@CR37]; Hrkach et al. [@CR39]; Jia et al. [@CR44]; Jinno et al. [@CR45]; Kaminskas et al. [@CR47], [@CR48]; Kato et al. [@CR49]; Kawabata et al. [@CR50]; Kurmi et al. [@CR52]; Larsen et al. [@CR53]; Manvelian et al. [@CR59], [@CR60]; Manjunath and Venkateswarlu [@CR58]; Matsumura et al. [@CR61]; Morgen et al. [@CR64]; Onoue et al. [@CR67], [@CR68], [@CR69], [@CR70], [@CR71], [@CR72], [@CR73], [@CR74]; Pandey et al. [@CR76]; Pathak and Nagarsenker [@CR77]; Piao et al. [@CR80]; Pepic´ et al. [@CR78]; Prajapati et al. [@CR81]; Reddy and Murthy [@CR82]; Reddy et al. [@CR83]; Sharma et al. [@CR86]; Strickley [@CR88]; Sylvestre et al. [@CR89]; Teshima et al. [@CR91]; Thomas et al. [@CR93], [@CR94]; Tomii [@CR95]; Watanabe et al. [@CR98]; Wu and Benet [@CR99]; Xia et al. [@CR100]; Zhang et al. [@CR101], [@CR102], [@CR103]). Polylysine dendrimer with doxorubicin, an intravenously administered anti-cancer nanomedicine, results in increased systemic exposure and tumor cell of doxorubicin. Poly(amidoamine) dendrimer with flurbiprofen is an intravenously injectable solution with increased distribution to the site of inflammation and increased in vivo retention time. PEGylated polylysine dendrimer with methotrexate or lactoferrin-conjugated dendrimer with methotrexate are intravenous formulations with prolonged systemic exposure and increased lung accumulation, respectively. Poly(amidoamine) dendrimer with piroxicam with is a formulation with increased systemic exposure.

### Engineered nanoparticle {#Sec5}

Engineered nanoparticles comprise nanocrystals, solumatrix fine particles, or nanosized amorphous particles, which can improve systemic exposure and decrease retention in the mucosal layer. They can be administered via various routes, but result in insufficient sustained release. Examples of engineered nanoparticle application include reducing gastric mucosal irritation due to NSAID nanomedicines, reducing other kinds of toxicity due to high Cmax compared to the original drug (Devalapally et al. [@CR14]; Kawabata et al. [@CR51]; Liu and Fréchet [@CR56]; Mora-Huertas et al. [@CR63]).

Carbendazim, cilostazol, curcumin, danazol, fenofibrate, megestrol acetate, nitrendipine, and tranilast are administered orally by increasing oral bioavailability (F) using nanocrystal formulations. Diclofenac and indomethacin formulations, using SoluMatrix™ fine particle technology, are oral formulations with improved absorption rates and pain relief. Nanosized amorphous particles of Nobilet show reduced hepatotoxicity (i.e., protection of liver function) with oral F. Inhalable nanocrystalline powder of Tranilast is a formulation administered directly to lungs and with improved anti-inflammatory effect. Albumin nanoparticles of paclitaxel improves targeting variability by increasing delivery to cancer cells when intravenously administered (Asthana et al. [@CR2]; Barenholz [@CR3]; Chaturvedi et al. [@CR9]; Fanciullino et al. [@CR24]; Feldman et al. [@CR29]; Fetterly and Straubinger [@CR30]; Hanafy et al. [@CR37]; Hrkach et al. [@CR39]; Jia et al. [@CR44]; Jinno et al. [@CR45]; Kaminskas et al. [@CR47], [@CR48]; Kato et al. [@CR49]; Kawabata et al. [@CR50]; Kurmi et al. [@CR52]; Larsen et al. [@CR53]; Manvelian et al. [@CR59], [@CR60]; Manjunath and Venkateswarlu [@CR58]; Matsumura et al. [@CR61]; Morgen et al. [@CR64]; Onoue et al. [@CR67], [@CR68], [@CR69], [@CR70], [@CR71], [@CR72], [@CR73], [@CR74]; Pandey et al. [@CR76]; Pathak and Nagarsenker [@CR77]; Piao et al. [@CR80]; Pepic´ et al. [@CR78]; Prajapati et al. [@CR81]; Reddy and Murthy [@CR82]; Reddy et al. [@CR83]; Sharma et al. [@CR86]; Strickley [@CR88]; Sylvestre et al. [@CR89]; Teshima et al. [@CR91]; Thomas et al. [@CR93], [@CR94]; Tomii [@CR95]; Watanabe et al. [@CR98]; Wu and Benet [@CR99]; Xia et al. [@CR100]; Zhang et al. [@CR101], [@CR102], [@CR103]).

### Lipid nanosystems {#Sec6}

Lipid nanosystems including emulsions, liposomes, solid-lipid nanoparticles, and lectin-modified solid lipids can be used to control the degradation and metabolism of the formulation and prolong systemic exposure. In addition, the selective delivery of pharmaceuticals can be improved and the pharmacological effect (e.g. anti-cancer effects in anti-cancer nanomedicines) can be enhanced by the increase of its accumulation in cancer tissues However, their disadvantages include rapid removal due to reticuloendothelial system (RES) uptake, limitation of administration routes, cytotoxicity risk due to low anti-genicity, and surfactant use for formulation (Devalapally et al. [@CR14]; Kawabata et al. [@CR51]; Liu and Fréchet [@CR56]; Mora-Huertas et al. [@CR63]).

Emulsions were formulated to increase oral F in both self-emulsifying and drug delivery systems, and several nanomedicines with emulsion formulations have been clinically used including cinnarizine, coenzyme Q10, cyclosporin A, halofantrine, and simvastatin. Inhalable dry emulsion of cyclosporin A is used to induce an anti-inflammatory effect in the lungs (Devalapally et al. [@CR14]; Kawabata et al. [@CR51]; Liu and Fréchet [@CR56]; Mora-Huertas et al. [@CR63]).

Differences in liposome constituents in liposome formulations have been documented in several reports (Asthana et al. [@CR2]; Barenholz [@CR3]; Chaturvedi et al. [@CR9]; Fanciullino et al. [@CR24]; Feldman et al. [@CR29]; Fetterly and Straubinger [@CR30]; Hanafy et al. [@CR37]; Hrkach et al. [@CR39]; Jia et al. [@CR44]; Jinno et al. [@CR45]; Kaminskas et al. [@CR47], [@CR48]; Kato et al. [@CR49]; Kawabata et al. [@CR50]; Kurmi et al. [@CR52]; Larsen et al. [@CR53]; Manvelian et al. [@CR59], [@CR60]; Manjunath and Venkateswarlu [@CR58]; Matsumura et al. [@CR61]; Morgen et al. [@CR64]; Onoue et al. [@CR67], [@CR68], [@CR69], [@CR70], [@CR71], [@CR72], [@CR73], [@CR74]; Pandey et al. [@CR76]; Pathak and Nagarsenker [@CR77]; Piao et al. [@CR80]; Pepic´ et al. [@CR78]; Prajapati et al. [@CR81]; Reddy and Murthy [@CR82]; Reddy et al. [@CR83]; Sharma et al. [@CR86]; Strickley [@CR88]; Sylvestre et al. [@CR89]; Teshima et al. [@CR91]; Thomas et al. [@CR93], [@CR94]; Tomii [@CR95]; Watanabe et al. [@CR98]; Wu and Benet [@CR99]; Xia et al. [@CR100]; Zhang et al. [@CR101], [@CR102], [@CR103]). Intravenous injectable solutions of amikacin and O-palmitoyl tilisolol in liposomes (Phospholipid/Chol) have been used for half-life extension, amphotericin B in liposomes (PC/Chol/DSPG) shows decreased systemic exposure and RES uptake, and cytarabine/daunorubicin in liposomes (DSPC/DSPG/Chol) has been used to reduce clearance. Pegylated liposome-treated doxorubicin results in increased distribution of doxotubicin to cancer tissues, and prednisolone in liposomes (PC/PG) or (PC/Chol/10% DSPE-PEG2000) results in prolonged systemic exposure. Solid-lipid nanoparticles of azidothymidine result in increased permeability to the brain, those of clozapine result in increased systemic exposure due to clearance reduction, those of diclofenac developed as a transdermal preparation result in increased transdermal absorption, and those of lidocaine as a transdermal preparation result in longer duration of drug efficacy by regulating skin permeability. A lectin-modified solid-lipid N of insulin shows increased oral F (Asthana et al. [@CR2]; Barenholz [@CR3]; Chaturvedi et al. [@CR9]; Fanciullino et al. [@CR24]; Feldman et al. [@CR29]; Fetterly and Straubinger [@CR30]; Hanafy et al. [@CR37]; Hrkach et al. [@CR39]; Jia et al. [@CR44]; Jinno et al. [@CR45]; Kaminskas et al. [@CR47], [@CR48]; Kato et al. [@CR49]; Kawabata et al. [@CR50]; Kurmi et al. [@CR52]; Larsen et al. [@CR53]; Manvelian et al. [@CR59], [@CR60]; Manjunath and Venkateswarlu [@CR58]; Matsumura et al. [@CR61]; Morgen et al. [@CR64]; Onoue et al. [@CR67], [@CR68], [@CR69], [@CR70], [@CR71], [@CR72], [@CR73], [@CR74]; Pandey et al. [@CR76]; Pathak and Nagarsenker [@CR77]; Piao et al. [@CR80]; Pepic´ et al. [@CR78]; Prajapati et al. [@CR81]; Reddy and Murthy [@CR82]; Reddy et al. [@CR83]; Sharma et al. [@CR86]; Strickley [@CR88]; Sylvestre et al. [@CR89]; Teshima et al. [@CR91]; Thomas et al. [@CR93], [@CR94]; Tomii [@CR95]; Watanabe et al. [@CR98]; Wu and Benet [@CR99]; Xia et al. [@CR100]; Zhang et al. [@CR101], [@CR102], [@CR103]).

### Micelles {#Sec7}

Micelles have advantages of high membrane permeability, and improved solubility and systemic exposure, but disadvantages of insufficient sustained release and cytotoxicity due to surfactant use (Devalapally et al. [@CR14]; Kawabata et al. [@CR51]; Liu and Fréchet [@CR56]; Mora-Huertas et al. [@CR63]). Block copolymeric micelles reduce clearance and increase systemic exposure of active pharmaceutical ingredients in intravenously administered formulations of camptothecin, doxorubicin, and paclitaxel. Block copolymer micelle allow direct administration to the eyeball increasing its efficacy. Self-micellizing solid dispersion of tranilast result in increased oral F (Asthana et al. [@CR2]; Barenholz [@CR3]; Chaturvedi et al. [@CR9]; Fanciullino et al. [@CR24]; Feldman et al. [@CR29]; Fetterly and Straubinger [@CR30]; Hanafy et al. [@CR37]; Hrkach et al. [@CR39]; Jia et al. [@CR44]; Jinno et al. [@CR45]; Kaminskas et al. [@CR47], [@CR48]; Kato et al. [@CR49]; Kawabata et al. [@CR50]; Kurmi et al. [@CR52]; Larsen et al. [@CR53]; Manvelian et al. [@CR59], [@CR60]; Manjunath and Venkateswarlu [@CR58]; Matsumura et al. [@CR61]; Morgen et al. [@CR64]; Onoue et al. [@CR67], [@CR68], [@CR69], [@CR70], [@CR71], [@CR72], [@CR73], [@CR74]; Pandey et al. [@CR76]; Pathak and Nagarsenker [@CR77]; Piao et al. [@CR80]; Pepic´ et al. [@CR78]; Prajapati et al. [@CR81]; Reddy and Murthy [@CR82]; Reddy et al. [@CR83]; Sharma et al. [@CR86]; Strickley [@CR88]; Sylvestre et al. [@CR89]; Teshima et al. [@CR91]; Thomas et al. [@CR93], [@CR94]; Tomii [@CR95]; Watanabe et al. [@CR98]; Wu and Benet [@CR99]; Xia et al. [@CR100]; Zhang et al. [@CR101], [@CR102], [@CR103]).

### Polymeric nanoparticles {#Sec8}

Polymeric nanoparticles include ethyl cellulose/casein, PLGA (PLGA and alginate), PLA-PEG, hydrogel, albumin and chitosan analogs with characteristics of relatively stable drug release and prolonged duration of action. However, there are a few cases in which initial rupture is inhibited, or administration routes are limited. In particular, it is necessary to consider factors involved in elimination of non-degradable polymers from the body (Devalapally et al. [@CR14]; Kawabata et al. [@CR51]; Liu and Fréchet [@CR56]; Mora-Huertas et al. [@CR63]).

Polymeric nanoparticles with increased F include ethyl cellulose/casein nanoparticles with celecoxib, PLGA and alginate nanoparticle with clotrimazole/econazole or rifampicin, hydrogel nanoparticle with insulin, and an oral formulation of siRNA using chitosan analog nanoparticles. An docetaxel IV formulation using PLA-PEG nanoparticles showed a prolonged anticancer effect due to increased half-life. IV or IP formulations of LGA nanoparticles with doxorubicin have been reported to show reduced toxicity through prolongation of half-life and reduction of cardiac distribution. Half-life extension and F increase are also reported in the case of PLGA nanoparticles with glucagon (Asthana et al. [@CR2]; Barenholz [@CR3]; Chaturvedi et al. [@CR9]; Fanciullino et al. [@CR24]; Feldman et al. [@CR29]; Fetterly and Straubinger [@CR30]; Hanafy et al. [@CR37]; Hrkach et al. [@CR39]; Jia et al. [@CR44]; Jinno et al. [@CR45]; Kaminskas et al. [@CR47], [@CR48]; Kato et al. [@CR49]; Kawabata et al. [@CR50]; Kurmi et al. [@CR52]; Larsen et al. [@CR53]; Manvelian et al. [@CR59], [@CR60]; Manjunath and Venkateswarlu [@CR58]; Matsumura et al. [@CR61]; Morgen et al. [@CR64]; Onoue et al. [@CR67], [@CR68], [@CR69], [@CR70], [@CR71], [@CR72], [@CR73], [@CR74]; Pandey et al. [@CR76]; Pathak and Nagarsenker [@CR77]; Piao et al. [@CR80]; Pepic´ et al. [@CR78]; Prajapati et al. [@CR81]; Reddy and Murthy [@CR82]; Reddy et al. [@CR83]; Sharma et al. [@CR86]; Strickley [@CR88]; Sylvestre et al. [@CR89]; Teshima et al. [@CR91]; Thomas et al. [@CR93], [@CR94]; Tomii [@CR95]; Watanabe et al. [@CR98]; Wu and Benet [@CR99]; Xia et al. [@CR100]; Zhang et al. [@CR101], [@CR102], [@CR103]).

Pharmacokinetic properties of nanomedicines {#Sec9}
-------------------------------------------

Pharmacokinetic characteristics of various nanomedicines with different formulations are determined by particle size, shape (chemical structure), and surface chemical characteristics (FDA [@CR28]). Nanomedicines with particle size less than 10 nm are removed by kidneys whereas those with particle size more than 10 nm are sometimes elongated and removed by the liver and/or the mononuclear-phagocyte system (MPS). The aim of regulating particle size in nanomedicines is to increase their retention in target tissues, and to remove them rapidly when distributed to non-target tissues. A protein corona is formed around nanomedicines by non-specific protein adsorption in body, but this is prevented by materials such as polyethylene glycol (PEG) applied on the nano-particle through surface coating. Such protein adsorption induces protein denaturation, which may lead to protein aggregation or phagocytosis due to activated macrophages. Nanoparticle targeting based on chemical properties of nanoparticles and surface coatings comprises active and passive targeting. Passive targeting is defined as non-specific accumulation in disease tissue (usually cancer tissue). This is especially applicable to solid cancers in which targeting results in increased blood vessel and transporter permeations and retention (enhanced permeability and retention, EPR effect) of nanomedicines, and their increased accumulation in tumor tissues. Specific or active targeting is defined as selective transport of nanomedicines containing protein, antibody, or small molecule only to specific tissues and/or specific cells. This may occur via homing to overexpressed cell-surface receptors.

Pharmacokinetic assessment of nanomedicine by regulatory agencies {#Sec10}
-----------------------------------------------------------------

As mentioned above, a wide variety of nanomedicine have been developed and approved for use in clinical practice and there are also a number of nanomedicines in clinical trials. As of 2016, 78 nanomedicines were on pharmaceutical markets across the world and 63 nanomedicines were approved as drugs or were in the approval process based on search results from '<http://www.clinicaltrial.gov>'. It would be meaningful to summarize key considerations of the approval authorities and use this knowledge for the development and approval of nanomedicines.

Food and Drug Administration (FDA) {#Sec11}
----------------------------------

Nanoscale materials as defined by the US FDA include nanomaterials (materials used in the manufacture of nanomedicine, additives, etc.) and final products (nanomedicine). The particle size of such materials is typically 1--100 nm and such nanomedicines tend to result in increased bioavailability, decreased dose, improved drug efficacy, and decreased toxicity. Improvements in physical properties through effective formulation have led to improved solubility, dissolution rate, oral bioavailability, targeting to specific organs or cells, and/or improved dosage/convenience, leading to dose reduction with less adverse reactions due to the constituent active pharmaceutical ingredients or surfactants (FDA [@CR28]).

### Status of nanomedicines approved by the FDA {#Sec12}

The FDA approved 51 nanomedicines by the year 2016, 40% of which were in clinical trials between 2014 and 2016 (Arnold et al. [@CR1]; Benbrook [@CR4]; Berges and Eligard [@CR5]; Bobo et al. [@CR6]; Desai et al. [@CR13]; Duncan [@CR16]; FDA [@CR25], [@CR27], [@CR28]; Foss [@CR31]; Foss et al. [@CR32]; Fuentes et al. [@CR34]; Green et al. [@CR35]; Hann and Prentice [@CR38]; Hu et al. [@CR40]; Ing et al. [@CR41]; James et al. [@CR43]; Johnson et al. [@CR46]; May and Li [@CR62]; Möschwitzer and Müller [@CR66]; Salah et al. [@CR85]; Shegokar and Müller [@CR87]; Taylor and Gercel-Taylor [@CR90]; Ur Rehman et al. [@CR96]; Wang-Gillam et al. [@CR97]) (Table [4](#Tab4){ref-type="table"}). Formulated nanomedicines approved by the FDA can be classified into polymer nanomedicines, micelles, liposomes, antibody-drug conjugates, protein nanoparticles, inorganic nanoparticles, hydrophilic polymers, and nanocrystals. Polymer nanomedicines are the simplest forms of nanomedicines and contain soft materials to increase solubility, biocompatibility, half-life and bioavailability as well as to control release of active pharmaceutical gradients from nanomedicines in body. In particular, Paxone^®^, Ulasta^®^, and PLEGRIDY^®^ formulated with the use of poly(ethylene glycol) (PEG) are representative polymer nanomedicines resulting in increased half-life and bioavailability in in vivo. Micelles include Estrasorb^®^, BIND-014, and CALAA-01 as controlled-release forms of lipophilic drugs. Liposomes have reduced toxicity and increased bioavailability, and include Onivyde^®^, Doxil^®^, Visudyne^®^, and Thermodox^®^. Antibody-drug conjugates (ADCs) have been used to reduce drug cytotoxicity and improve solubility (PEGylation). ADCs are stable in blood and within targeted cancer cells and are expected to be released into intracellular or paracellular compartments after uptake. The pairing and linkage of antibody and drug are important, and are critical factors for their slow clearance and long half-life (approximately 3 and 4 days). Brentuximab emtasine is an example of an ADC nanomedicine which addresses safety issues by reducing toxicity of monomethyl auristane E. In this case, maleimide linkage and conjugation with thiolated antibody results in the release of only 2% monomethyl auristane E even 10 days after administration. ADCs with non-cleavable linkages such as those with tratuzumab are also available. Nanomedicines using protein nanoparticles include Abraxane^®^, an albumin-bound paclitaxel, and Ontak^®^, an engineered fusion protein, which consist of endogenous or engineered protein carriers. Inorganic nanoparticles in nanomedicine are drug formulations commonly used for treatment and/or imaging, in which metallic and metal oxide materials are used. Coating with hydrophilic polymers (dextran or sucrose) such as iron oxide is used for iron supplements including Venofer^®^, Ferrlecit^®^, INFed^®^, Dexferrum^®^, and Feraheme^®^, which show slow dissolution patterns after intravenous administration and less toxicity due to free iron in high dosage regimens. Because poor absorption of free iron is one of the reasons for increasing iron dosage resulting in severe toxicity, an iron oxide nanomedicine formulation with iron supplementation is clinically meaningful. Inorganic nanomedicines using gold are based on thermal and surface chemistry of gold, and it have not yet been approved by the FDA. Several clinical investigations using nanomedicines formulated with gold have been conducted. CYP-6091 containing colloidal gold with recombinant human tumor necrosis factor rhTNF is in a phase 2 trial, NBTXR3 and PEP503 are radio enhancers containing hifnium metal oxide for brain tumor treatment and inorganic silica nanoparticles for fluorescence-based cancer imaging, respectively, and are in phase 1 trials. Nanocrystal formulations increase nanoscale dimensions and improve dissolution and solubility and include Rapamune^®^, Tricor^®^, Emend^®^, and Megace ES^®^.

Table 4Nanomedicines approved by FDAFormulationsProduct namesPharmaceutical companyIndicationsCharacteristicsApproval yearPolymer NP: synthetic polymer particles PEGylated adenosine deaminase enzymeAdagen^®^/pegademase bovineSigma-Tau\
PharmaceuticalsSerious immunodeficiency therapyImproved circulation (retention) in body and decreased immunogenicity1990 PEGylated antibody fragment (Certolizumab)Cimzia^®^/certolizumabpegolUCBChron's disease, rheumatoid arthritis, psoriasis, ankylosing spondylitisImproved circulation (retention) in body and stability2008\
2009\
2013 Random copolymer of [l]{.smallcaps}-glutamate, [l]{.smallcaps}-alanine, [l]{.smallcaps}-lysine and [l]{.smallcaps}-tyrosineCopaxone^®^/GlatopaTevaMultiple sclerosisRegulation of CL by large amino-acid polymers1996 Leuprolide acetate and polymer \[PLGH(poly([dl]{.smallcaps}-lactide-coglycolide)\]Eligard^®^TolmarProstate cancerRegulation of drug delivery by prolongation of circulation (retention) in body2002 PEGylated anti-VEGF aptamer (vascular endothelial growth factor) aptamerMacugen^®^/PegaptanibBausch&LombDecreased visionImproved aptamier stability by PEGylation2004 Chemically synthesized ESA (erythropoiesis-stimulating agent)Mircera^®^/Methoxy PEG glycol-epoetin βHoffman-LaRocheAnemia with chronic renal failureImproved aptamier stability by PEGylation2007 PEGylated GCSF proteinNeulasta^®^/pegfilgrastimAmgenLeukopenia by chemotherapyImproved protein stability by PEGylation2002 PEGylated IFN alpha-2a proteinPegasys^®^GenentechHepatitis B and CImproved protein stability by PEGylation2002 PEGylated IFN alpha-2b proteinPegIntron^®^MerckHepatitis CImproved protein stability by PEGylation2001 Poly(allylamine hydrochloride)Renagel^®^\
\[sevelamer HCl\]/Renagel^®^\
\[sevelamer carbonate\]SanofiChronic renal failureRegulation of drug delivery by prolongation of circulation (retention) in body and increased target delivery2000 PEGylated HGH receptor antagonistSomavert^®^/pegvisomantPfizerAcromegalyImproved protein stability by PEGylation2003 Polymer-protein conjugate PEGylated [l]{.smallcaps}-asparaginaseOncaspar^®^/pegaspargaseEnzonPharmaceuticalsAcute lymphocytic blood clotImproved protein stability by PEGylation1994 Polymer-protein conjugate (PEGylated porcine-likeuricase)Krystexxa^®^/pegloticaseHorizonChronic goutImproved protein stability by PEGylation2010 Polymer-protein conjugate (PEGylated IFNbeta-1a)Plegridy^®^BiogenMultiple sclerosisImproved protein stability by PEGylation2014 Polymer-protein conjugate (PEGylated factor VIII)ADYNOVATEBaxaltaHemophiliaImproved protein stability by PEGylation2015Liposome Liposomal daunorubicinDaunoXome^®^GalenKarposi sarcomaIncreased drug delivery to tumor cells and decreased systemic toxicity1996 Liposomal cytarabineDepoCyt©Sigma-TauLymphomaIncreased drug delivery to tumor cells and decreased systemic toxicity1996 Liposomal vincristineMarqibo^®^Onco TCSAcute lymphocytic blood clotIncreased drug delivery to tumor cells and decreased systemic toxicity2012 Liposomal irinotecanOnivyde^®^MerrimackPancreatic cancerIncreased drug delivery to tumor cells and decreased systemic toxicity2015 Liposomal amphotericin BAmBisome^®^Gilead SciencesFungal infectionReduced renal toxicity1997 Liposomal morphine sulphateDepoDur^®^Pacira PharmaceuticalsLoss of pain due to surgeryProlonged exposure2004 Liposomal verteporfinVisudyne^®^Bauschand LombDecreased vision, Ophthalmic hiscomaplastiaImproved drug delivery to lesion vessels and photosensitivity2000 Liposomal doxorubicinDoxil^®^/Caelyx™JanssenKarposi sarcoma, ovarian cancer, Multiple myelomaIncreased drug delivery to target sites and decreased systemic toxicity1995\
2005\
2008 Liposomal amphotericinB lipid complexAbelcet^®^Sigma-tauFungal infectionReduced toxicity1995 Liposome-proteins SP-band SP-CCurosurf^®^/PoractantalphaChieseifarmaceuticiLung activator for stress disorderIncreased drug delivery at low dose and decreased toxicity1999Micelles Micellar estradiolEstrasorb™NovavaxMenopause hormone TherapyClinically release control2003 Protein NP Albumin-bound paclitaxel NPAbraxane^®^/ABI-007CelgeneBreast cancer, non-small cell lung cancer, pancreatic cancerImproved solubility and drug delivery to target tissues2005\
2012\
2013 Engineered protein combining L-2 and diphtheria toxinOntak^®^Eisai IncT-Cell lymphomaT cell-selective targeting1999Nanocrystal AprepitantEmend^®^MerckVomiting agentRapid absorption and increased F2003 FenofibrateTricor^®^Lupin AtlantisHyperlipidemiaIncreased F2004 SirolimusRapamune^®^Wyeth\
PharmaceuticalsImmunosupressantIncreased F and decreased dose2000 Megestrol acetateMegaceES^®^Par PharmaceuticalsAnorexiaIncreased F and decreased dose2001 Morphine sulfateAvinza^®^PfizerMental stimulantIncreased F and decreased dose2002\
2015 Dexamethyl-phenidate HClFocalin XR^®^NovartisMental stimulantIncreased F and decreased dose2005 Metyhlphenidate HClRitalin LA^®^NovartisMental stimulantIncreased F and decreased dose2002 Tizanidine HClZanaflex^®^AcordaMuscle relaxantIncreased F and decreased dose2002 Calcium phosphateVitoss^®^StrykerBone substituteImitation of bone structure by cell adhesion and growth2003 HydroxyapatiteOstim^®^Heraseus KulzerBone substituteImitation of bone structure by cell adhesion and growth2004 HydroxyapatiteOsSatura^®^IsoTis OrthobiologicsBone substituteImitation of bone structure by cell adhesion and growth2003 HydroxyapatiteNanOss^®^Rti SurgicalBone substituteImitation of bone structure by cell adhesion and growth2005 HydroxyapatiteEquivaBone^®^Zimmer BiometBone substituteImitation of bone structure by cell adhesion and growth2009 Paliperidone PalmitateInvega^®^Sustenna^®^Janssen PharmsSchizoaffective disorderControl of slow release rate in drugs with low solubility2009\
2014 Dantrolene sodiumRyanodex^®^Eagle PharmaceuticalsMalignant benign hypothermiaRapid absorption at high dose2014Inorganic/metallic NPs Iron oxideNanotherm^®^MagForceHybrid speciesVertical irritant effect by increased uptake2010 Ferumoxytol SPION with poly glucose sorbitol carboxy methyletherFeraheme™/ferumoxytolAMAG pharmaceuticalsChronic renal failure with iron deficiencyExtended release and reduced dose2009 Iron sucroseVenofer^®^Luitpold\
PharmaceuticalsChronic renal failure with iron deficiencyIncreased dose capacity2000 Sodium ferric gluconateFerrlecit^®^Sanofi AvertisChronic renal failure with iron deficiencyIncreased dose capacity1999 Iron dextran (low MW)INFeD^®^Sanofi AvertisChronic renal failure with iron deficiencyIncreased dose capacity1995 Iron dextran (high MW)DexIron^®^/Dexferrum^®^Sanofi AvertisChronic renal failure with iron deficiencyIncreased dose capacity1997 SPION coated with dextranFeridex^®^/Endorem^®^AMAG pharmaceuticalsImaging materialsVertical irritant effect1996\
2008 SPION coated with dextranGastroMARK™/umirem^®^AMAG pharmaceuticalsImaging materialsVertical irritant effect2001\
2009

### Suggested considerations for the evaluation of nanomedicines by the FDA {#Sec13}

Based on guidelines and reports from the FDA, considerations for evaluation of nanomedicines are as follows. Evaluation of nano-formulation properties of nanomedicines comprises evaluating physicochemical properties of the nanomaterials, constituents and proportions of the nanomaterials, and quality and manufacturing of the nanomaterials (Eifler and Thaxton [@CR18]; FDA [@CR26]). First, pharmacokinetics of nanomedicines are assessed in the context of their systemic exposure considering (1) rate and amount of absorption and retention in circulation based on blood concentration over time, (2) relationship between prolongation of half-life and whole body exposure duration, and (3) bioavailability changes (Eifler and Thaxton [@CR18]; FDA [@CR26], [@CR28]). Second, assessment of nanomedicine distribution to blood and tissue is recommended to be done based on apparent volume of distribution, and distribution or accumulation to positive targeting sites based on time-dependent changes. Third, in the context of metabolism, it is important to evaluate whether decomposition or metabolism of nano-formulations or their active pharmaceutical ingredients occur. Fourth, elimination of raw materials used in nano-formulations, and products from decomposition and/or metabolism of nano-formulations and their active pharmaceutical ingredients are recommended for evaluation. The accumulation of nano-formulations in target tissues and elimination through MPS are also investigated. Finally, toxicity assessment of nanomedicines needs to be conducted.

EMA {#Sec14}
---

In 2011, the EMA defined nanomedicines as drugs composed of nanomaterials 1--100 nm in size, and these are classified into liposomes, nanoparticles, magnetic NPs, gold NPs, quantum dots, dendrimers, polymeric micelles, viral and non-viral vectors, carbon nanotubes, and fullerenes (EFSA [@CR19]; EMA [@CR22]).

### Status of nanomedicines approved by the EMA {#Sec15}

The EMA has approved 8 of the 11 commercially available nanomedicine drugs developed as first-generation nanomedicines (such as liposomes or iron-containing formulations), and three of them were withdrawn. Investigations were conducted to establish the scientific basis for efficacy and safety of 12 nanomedicines, and were evaluated via the European Medicines Agency (EMA) approval process. Following this initial process, 48 nano medicines or imaging materials are currently in clinical trials (Phase 1--Phase 3) in the EU. In addition, preclinical trials are underway for a number of nanomedicine products (Draca et al. [@CR15]; Ehmann et al. [@CR17]; Hafner et al. [@CR36]; Lawrence and Rees [@CR54]; Ling et al. [@CR55]; Shegokar and Müller [@CR87]) (Table [5](#Tab5){ref-type="table"}).

Table 5Nanomedicines approved by EMAFormulationsAPIProduct namePharmaceutical companyAdministration routeIndicationsNanocrystalsAprepitanEmend^®^Merck Sharp and Dohme BVCapsuleVomiting after surgeryFenofibrateTricor^®^/Lipanthyl^®^/Lipidil^®^Recipharm, FRTabletHyperlipidemiaOlanzapineZypadhera^®^Lilly PharmaPowder/solventSchizophreniaPaliperidoneXeplion^®^Janssen Pharmaceutica NVProlonged release suspension for injection (im)SchizophreniaSirolimusRapamune^®^Pfizer Ireland Pharmaceuticals, IETabletKidney transplantation rejectionNanoemulsionsCyclosporineNorvir^®^Aesica Queenborough LtdSoft capsulesHIV infection, kidney transplantation rejectionPegaspargase (mPEG-asparaginase)Oncaspar^®^Sigma-tau Arzneimittel GmbHSolution (iv/im)Acute lymphocytic leukemiaSevelamerRenagel^®^/Renvela^®^Genzyme LtdTabletDialysis, hyperphosphatemiaPolymer-protein conjugatesAmphotericin BAmBisome^®^Gilead SciencesSuspension (iv)Fungal infectionCertolizumabpegol (PEG-anti-TNFFab)Cimzia™UCB Pharma SASolution (sc)Rheumatoid arthritisMethoxypolyethylene glycol-epoetin betaMircera^®^Roche PharmaSolution (iv/sc)Anemia, chronic renal failurePegfilgrastim (PEG-rhGCSF)Neulasta^®^Amgen TechnologySolution (sc)Leukopenia by chemotherapyPeginterferonalpha-2a (mPEG-interferon alpha-2a)Pegasys^®^Roche PharmaSolution (sc)HBV/HCV infectionPeginterferonalpha-2b (mPEG-interferon alpha-2b)PegIntron^®^Schering-PloughSolution for injection (sc)HIV inflammationPegvisomant (PEG-HGH antagonist)Somavert^®^Pfizer ManufacturingSolution for injection (sc)Peripheral hypertrophyLiposomesCytarabineDepoCyt^®^Almac PharmaSuspension (intrathecal)Brain cancerDaunorubicinDaunoXome^®^Gilead Sciences LtdSuspension (iv)Kaposi sarcoma by HIVDoxorubicinMyocet^®^GP-PharmSuspension (iv)Breast cancerDoxorubicinCaelyx^®^Janssen PharmaceuticalSuspension (iv)Breast cancer, ovarian cancer, Kaposi sarcomaMifamurtideMepact^®^TakedaSuspension (iv)MyosarcomaMorphineDepoDur^®^Almac PharmaSuspension(epidural)PainPaclitaxelAbraxane^®^CelgenePowder for suspensionBreast cancerPropofolDiprivan^®^/Propofol-Lipuro^®^/Propofol^®^Astra ZenecaEmulsion (iv)AnesthesiaVerteporfinVisudyne^®^Novartis Pharma GmbH, NürnbergSuspension (iv)Decreased vision, myopiaNanoparticlesInactivated hepatitis A virusEpaxal^®^CrucellSuspension (iv)Hepatitis A vaccines90Y-ibritumomab tiuxetanZevalin^®^Bayer PharmaSolution (iv)LymphomaVirosomesAdjuvanted influenza vaccineInflexal^®^ VCrucellSuspension (iv)Influenza vaccinesGlatiramer (Glu,Ala,Tyr,Lys copolymer)Copaxone^®^Teva PharmaceuticalsSolution (sc)Multiple sclerosisPolymeric drugsSodium ferric gluconateFerrlecit^®^Aventis PharmaSolution (iv)Anemia with iron deficiencyNanocomplexFerric carboxymaltoseFerinject^®^ViforSolution (iv)Iron deficiencyFerumoxytolRienso^®^TakedaSolution (iv)Anemia with iron deficiency, chronic renal failureIron sucrose \[iron(III)-hydroxidesucrose complex\]Visudyne^®^NovartisSolution (iv)Iron deficiencyIron(III) isomaltosideMonofer^®^PharmacosmosSolution (iv)Iron deficiencyIron(III)-hydroxide dextran complexFerrisat^®^/Cosmofer^®^PharmacosmosSolution (iv)Iron deficiency

### Suggesting points for the evaluation of nanomedicines in EMA {#Sec16}

EMA presents that pharmacokinetic and pharmacodynamic properties of nanomedicines were determined by chemical composition and physicochemical properties. So, EMA suggest to consider six possibilities to evaluate nanomedicines considering the chemical composition and physicochemical properties (EFSA [@CR19]; TGA [@CR92]) including (1) nano-formulations are unstable at the time of manufacture and are converted into non-nanosized form, (2) the state of conversion into non-nanosized form when the drug substance in the manufacturing site is present as a matrix, (3) conversion to non-nanosized forms due to lack of bio-similarity under in vitro non-stable conditions, (4) conversion from nano-forms to non-nanosized forms during toxicity assessment (5) co-existence of nano forms and non-nano forms at the in vivo administration site, and (6) existence of the nano form in biological samples and tissues after absorption. In view of these various considerations for nanomedicine evaluation, EMA suggested the need to discuss the following aspects for the evaluation of nanomedicines (EFSA [@CR19]; EMA [@CR22], [@CR23]; Ehmann et al. [@CR17]; TGA [@CR92]). Overall, physicochemical properties, stability, and functionality of nanomedicines should be evaluated. To this end, interactions and reactivity with biointerfaces due to coatings or additives in the final nanomedicines, suitability of biomarkers of in vivo functionality of nanomedicines, in vivo distribution and bio-persistence of nanomedicines, long-term safety of decomposition products, and adequacy of dose and dose interval settings have emerged as key factors for the evaluation process. Notably, liposome formulations, iron-based formulations, and nanocrystal formulations which can be considered first-generation nanomedicines and have already been marketed and used, have proved their effectiveness and safety over a long period. Based on this status, evaluation methods for approval of second-generation nanomedicines have been suggested for consideration (Ehmann et al. [@CR17]; EMA [@CR20], [@CR21], EMA [@CR23]).

Future perspectives on nanomedicines considering their pharmacokinetic properties {#Sec17}
---------------------------------------------------------------------------------

Given the considerations for development and use of nanomedicines, indispensable steps to attain clinical significance include assessment of the nature of formulations, pharmacokinetic properties, and the approval process for nanomedicines. Therefore, based on recent trends in nanomedicine development and guidelines of the FDA and EMA, we propose a simple algorithm to guide the recommended ADME evaluations of nanomedicines (Fig. [1](#Fig1){ref-type="fig"}). In the proposed algorithm, stability in the manufacturing process and simulated human conditions determine whether ADME properties of the drugs of interest are assessed or not. Assessment varies based on administration routes and distribution. For example, evaluation varies based on whether orally administered nanomedicines are found in nano forms or non-nano forms in the gastro-intestinal tract. Thus, the proposed algorithm provides critical and practical checkpoints in nanomedicine development and assessment.

Fig. 1A proposed new algorithm to assess ADME of nanomedicines
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